Matches in SemOpenAlex for { <https://semopenalex.org/work/W2085402595> ?p ?o ?g. }
- W2085402595 endingPage "806" @default.
- W2085402595 startingPage "802" @default.
- W2085402595 abstract "Purpose To evaluate the correlation between improvement in visual acuity and the reduction of foveal thickness after a single intravitreal injection of 4 mg of triamcinolone in diabetic macular edema. Design Prospective, interventional, nonrandomized clinical trial. Method patients In a prospective study 24 eyes with diabetic macular edema were treated with an intravitreal injection of 4 mg of triamcinolone acetonide. main outcome measures: Best-corrected logMAR visual acuity and optical coherence tomography were performed at baseline and 3 months after the treatment. Results At baseline the average foveal thickness was 462 ± 154 μm (95% confidence interval, 397–527 μm) and at 3 months 257 ±114 μm (95% confidence interval, 209–305 μm) (P < .0001). The best-corrected logMAR average visual acuity was 60.5 ± 10.5 (95% confidence interval, 56.0–65.0) ETDRS letters at baseline compared with 65.5 ± 11.1 (95% confidence interval, 60.8–70.1) 3 months after the injection (P = .0001). There was no correlation between the improvement in visual acuity and the reduction of foveal thickness (r = 0.054, P = .8), but there was a correlation between reduction in foveal thickness and the age of the patients (r = 0.53, P = .008). Conclusion A single injection of 4 mg of intravitreal triamcinolone acetonide effectively reduces the foveal thickness in diabetic macular edema and improves visual acuity, but there does not appear to be a strong correlation between the reduction of foveal thickness and the improvement in visual acuity. To evaluate the correlation between improvement in visual acuity and the reduction of foveal thickness after a single intravitreal injection of 4 mg of triamcinolone in diabetic macular edema. Prospective, interventional, nonrandomized clinical trial. patients In a prospective study 24 eyes with diabetic macular edema were treated with an intravitreal injection of 4 mg of triamcinolone acetonide. main outcome measures: Best-corrected logMAR visual acuity and optical coherence tomography were performed at baseline and 3 months after the treatment. At baseline the average foveal thickness was 462 ± 154 μm (95% confidence interval, 397–527 μm) and at 3 months 257 ±114 μm (95% confidence interval, 209–305 μm) (P < .0001). The best-corrected logMAR average visual acuity was 60.5 ± 10.5 (95% confidence interval, 56.0–65.0) ETDRS letters at baseline compared with 65.5 ± 11.1 (95% confidence interval, 60.8–70.1) 3 months after the injection (P = .0001). There was no correlation between the improvement in visual acuity and the reduction of foveal thickness (r = 0.054, P = .8), but there was a correlation between reduction in foveal thickness and the age of the patients (r = 0.53, P = .008). A single injection of 4 mg of intravitreal triamcinolone acetonide effectively reduces the foveal thickness in diabetic macular edema and improves visual acuity, but there does not appear to be a strong correlation between the reduction of foveal thickness and the improvement in visual acuity." @default.
- W2085402595 created "2016-06-24" @default.
- W2085402595 creator A5001215128 @default.
- W2085402595 creator A5022956208 @default.
- W2085402595 creator A5036325960 @default.
- W2085402595 creator A5043367554 @default.
- W2085402595 date "2005-05-01" @default.
- W2085402595 modified "2023-10-18" @default.
- W2085402595 title "Relation Between Reduction of Foveal Thickness and Visual Acuity in Diabetic Macular Edema Treated With Intravitreal Triamcinolone" @default.
- W2085402595 cites W1485105115 @default.
- W2085402595 cites W1852829837 @default.
- W2085402595 cites W1977790296 @default.
- W2085402595 cites W1978199957 @default.
- W2085402595 cites W1995363602 @default.
- W2085402595 cites W1997013893 @default.
- W2085402595 cites W2000552582 @default.
- W2085402595 cites W2001453091 @default.
- W2085402595 cites W2001873710 @default.
- W2085402595 cites W2015033282 @default.
- W2085402595 cites W2048105668 @default.
- W2085402595 cites W2052023322 @default.
- W2085402595 cites W2069421922 @default.
- W2085402595 cites W2083092631 @default.
- W2085402595 cites W2110175853 @default.
- W2085402595 cites W2135333970 @default.
- W2085402595 cites W2149187593 @default.
- W2085402595 cites W2159723361 @default.
- W2085402595 cites W2165265638 @default.
- W2085402595 cites W2166108068 @default.
- W2085402595 cites W2170353976 @default.
- W2085402595 cites W2287479431 @default.
- W2085402595 cites W2314875344 @default.
- W2085402595 cites W2396658537 @default.
- W2085402595 cites W2406931263 @default.
- W2085402595 cites W2546961712 @default.
- W2085402595 cites W3202352366 @default.
- W2085402595 doi "https://doi.org/10.1016/j.ajo.2004.12.054" @default.
- W2085402595 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15860283" @default.
- W2085402595 hasPublicationYear "2005" @default.
- W2085402595 type Work @default.
- W2085402595 sameAs 2085402595 @default.
- W2085402595 citedByCount "98" @default.
- W2085402595 countsByYear W20854025952012 @default.
- W2085402595 countsByYear W20854025952013 @default.
- W2085402595 countsByYear W20854025952014 @default.
- W2085402595 countsByYear W20854025952015 @default.
- W2085402595 countsByYear W20854025952016 @default.
- W2085402595 countsByYear W20854025952017 @default.
- W2085402595 countsByYear W20854025952018 @default.
- W2085402595 countsByYear W20854025952019 @default.
- W2085402595 countsByYear W20854025952020 @default.
- W2085402595 countsByYear W20854025952023 @default.
- W2085402595 crossrefType "journal-article" @default.
- W2085402595 hasAuthorship W2085402595A5001215128 @default.
- W2085402595 hasAuthorship W2085402595A5022956208 @default.
- W2085402595 hasAuthorship W2085402595A5036325960 @default.
- W2085402595 hasAuthorship W2085402595A5043367554 @default.
- W2085402595 hasConcept C118487528 @default.
- W2085402595 hasConcept C126322002 @default.
- W2085402595 hasConcept C134018914 @default.
- W2085402595 hasConcept C141071460 @default.
- W2085402595 hasConcept C188816634 @default.
- W2085402595 hasConcept C2778257484 @default.
- W2085402595 hasConcept C2778818243 @default.
- W2085402595 hasConcept C2778903070 @default.
- W2085402595 hasConcept C2779829184 @default.
- W2085402595 hasConcept C2780347916 @default.
- W2085402595 hasConcept C2780827179 @default.
- W2085402595 hasConcept C2985127711 @default.
- W2085402595 hasConcept C30181142 @default.
- W2085402595 hasConcept C44249647 @default.
- W2085402595 hasConcept C555293320 @default.
- W2085402595 hasConcept C71924100 @default.
- W2085402595 hasConceptScore W2085402595C118487528 @default.
- W2085402595 hasConceptScore W2085402595C126322002 @default.
- W2085402595 hasConceptScore W2085402595C134018914 @default.
- W2085402595 hasConceptScore W2085402595C141071460 @default.
- W2085402595 hasConceptScore W2085402595C188816634 @default.
- W2085402595 hasConceptScore W2085402595C2778257484 @default.
- W2085402595 hasConceptScore W2085402595C2778818243 @default.
- W2085402595 hasConceptScore W2085402595C2778903070 @default.
- W2085402595 hasConceptScore W2085402595C2779829184 @default.
- W2085402595 hasConceptScore W2085402595C2780347916 @default.
- W2085402595 hasConceptScore W2085402595C2780827179 @default.
- W2085402595 hasConceptScore W2085402595C2985127711 @default.
- W2085402595 hasConceptScore W2085402595C30181142 @default.
- W2085402595 hasConceptScore W2085402595C44249647 @default.
- W2085402595 hasConceptScore W2085402595C555293320 @default.
- W2085402595 hasConceptScore W2085402595C71924100 @default.
- W2085402595 hasIssue "5" @default.
- W2085402595 hasLocation W20854025951 @default.
- W2085402595 hasLocation W20854025952 @default.
- W2085402595 hasOpenAccess W2085402595 @default.
- W2085402595 hasPrimaryLocation W20854025951 @default.
- W2085402595 hasRelatedWork W1985942700 @default.
- W2085402595 hasRelatedWork W2023613318 @default.
- W2085402595 hasRelatedWork W2095328482 @default.
- W2085402595 hasRelatedWork W2283340763 @default.